Parental Acceptance of Nirsevimab for RSV Prevention in Infants Across Two Consecutive Seasons in Emilia-Romagna, Italy [PDF]
VaccinesBackground: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab, a long-acting monoclonal antibody, provides single-dose protection during the RSV season, but the ...
Susanna Esposito +10 more
doaj +4 more sources
Cytokine Profile Changes in Infants With Respiratory Syncytial Virus Bronchiolitis With Nirsevimab [PDF]
Pediatr PulmonolPediatric Pulmonology, Volume 61, Issue 11, November 2026.
José Antonio Cañas +9 more
wiley +2 more sources
Coverage, Timing, Safety, and Determinants of Neonatal Intensive Care Unit Admission in Newborns Receiving Nirsevimab Prophylaxis for Respiratory Syncytial Virus [PDF]
PathogensBackground: Nirsevimab, a long-acting monoclonal antibody targeting respiratory syncytial virus (RSV), has recently been introduced as universal prophylaxis in newborns and infants. Although clinical trials have shown high efficacy and a favorable safety
Maria Costantino +20 more
doaj +3 more sources
Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review
VaccinesRespiratory syncytial virus (RSV) is the primary etiological agent responsible for lower respiratory tract infections (LRTIs) and hospitalizations among infants. Nirsevimab, a novel monoclonal antibody (mAb), offers sustained protection against RSV for a
Pan-Pan Wu, Fang-Rui Ding
doaj +2 more sources
Multicentre study on nirsevimab: Bayesian analysis reveals persisting risk for preterm infants [PDF]
BMJ Paediatrics OpenObjective To evaluate whether the timing and effectiveness of nirsevimab prophylaxis vary by gestational age.Design Retrospective cohort study conducted during two identical epidemic seasons: 2023–2024 (before nirsevimab introduction) and 2024–2025 ...
Federico Marchetti +13 more
doaj +2 more sources
RSV Monoclonal Antibody Implementation for At‐Risk Infants: Victoria, Australia's 2024 Experience [PDF]
Health Science Reports, Volume 9, Issue 9, September 2026.ABSTRACT Background New respiratory syncytial virus (RSV) preventative programs are launching globally. Our Australian jurisdiction implemented RSV monoclonal antibody provision via pediatric and perinatal hospitals for highest risk neonates and infants.
Jane Tuckerman +8 more
wiley +2 more sources
Uptake of Respiratory Syncytial Virus Prefusion F Protein Vaccination during Pregnancy and nirsevimab among Infants over Two Seasons in a Single Health System [PDF]
Journal of Pediatrics: Clinical PracticeObjective: To describe the uptake of respiratory syncytial virus (RSV) prevention products during the first 2 seasons after availability in the US in a large health system. Study design: Using multisource immunization data from a single health system, we
Jessica E. Kerr, MPH +3 more
doaj +2 more sources
Assessing the Effects of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis Outcomes: Insights From A Two‐Season Analysis [PDF]
Pediatric Pulmonology, Volume 61, Issue 10, October 2026.ABSTRACT Objectives Nirsevimab was approved in Europe in 2022 for respiratory syncytial virus (RSV) prevention. In October 2023, Catalonia (Spain) launched a universal immunization program for infants under 6 months during their first RSV season. This study aims to assess the characteristics of patients admitted with bronchiolitis following nirsevimab ...
Marta Agüera +12 more
wiley +2 more sources
The New Era of Respiratory Syncytial Virus Protection for Infants: A Mini Review of Current Tools for Immunoprophylaxis [PDF]
Acta Paediatrica, Volume 115, Issue 11, Page 2466-2472, November 2026.ABSTRACT Aim This mini review describes the history of infant respiratory syncytial virus (RSV) immunoprophylaxis and the latest advances in this area. It also reviews the efficacy, safety and impact of the recently introduced prophylactic strategies. Method This narrative review is based on a targeted review of published literature, with emphasis on ...
Santtu Heinonen, Pekka Vartiainen
wiley +2 more sources
Clinical and Translational ScienceRespiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants worldwide. Nirsevimab, an extended half‐life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory ...
Xiaomeng Mao +12 more
doaj +2 more sources